Hasten

What Hasten does

Hasten Biopharmaceutical Co., Ltd. (海森生物医药有限公司) is a privately held Chinese biopharmaceutical company founded in September 2020 and headquartered in Hefei, Anhui Province. It integrates R&D, manufacturing, and commercialization across the pharmaceutical value chain, focusing on chronic disease (cardiovascular, metabolic) and critical care therapeutic areas. The company was co-founded by CBC Group (Asia's largest healthcare-focused private equity firm), Hefei Industry Investment Group, and Feidong County government, and in April 2023 closed a US$315 million private equity round co-led by CBC Group and Mubadala Investment Company at a US$945 million post-money valuation.

Hasten's commercial portfolio comprises seven established originator drugs acquired from multinational pharmaceutical companies: five cardiovascular and metabolic brands from Takeda (Edarbi/azilsartan, Blopress/candesartan, Ebrantil/urapidil, Basen/voglibose, Actos/pioglitazone), Rocephin (ceftriaxone) from Roche, and Stilamin (somatostatin) from Merck. Its in-development pipeline includes Lerodalcibep (HST101), a third-generation PCSK9 fusion-protein inhibitor licensed from LIB Therapeutics for Greater China, with Phase 3 China topline results announced in August 2025 and FDA BLA filed by partner LIB in December 2024. The company holds MAH rights in Greater China and Switzerland for Stilamin, and has completed 70 Marketing Authorization Transfers across 8 Asia-Pacific countries.

Hasten operates a hybrid commercial model combining a 500-1,000 person field sales force (over 85% of employees serve frontline customers) with strategic distribution partnerships — including Sinopharm, Jointown Group, and China Resources Medical Commercial Group in China, and DKSH in Thailand. Its geographic footprint spans mainland China, Hong Kong, Taiwan, South Korea, Singapore, Thailand, Malaysia, Australia, Germany, and Switzerland. Revenue streams include branded pharmaceutical product sales, licensing and royalty income (e.g., Lerodalcibep milestones and royalties from LIB Therapeutics), and commercialization service fees (e.g., the December 2025 agreement with Everest Medicines). The Hefei production base (broke ground November 2022, 190M RMB, 25 acres) is expected to begin production in 2025, supporting the company's shift from pure commercialization toward integrated manufacturing.

Name

Hasten

Legal name

海森生物医药有限公司

Website

https://hastenpharma.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Hasten is a Chinese biopharmaceutical company founded in 2020 that integrates R&D, manufacturing, and commercialization across cardiovascular, metabolic, and critical care therapeutic areas in China and Asia-Pacific. It commercializes seven originator drugs acquired from Takeda, Roche, and Merck, and is developing Lerodalcibep, an in-licensed PCSK9 inhibitor.

Ownership category

akta.pro rank

Product category

Branded Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)

akta.pro secondary industries

Cardiology & Vascular Specialty Pharmaceuticals (HLAIACAG), Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA)

Keywords

• Branded pharmaceuticals
• Cardiovascular therapeutics
• Chronic disease drugs
• Critical care medicines
• Pharmaceutical commercialization

Headquarters

HQ city

Hefei

HQ country

China

HQ region

Asia

Offices7 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Revenue generated from sales of branded pharmaceutical products across cardiovascular, metabolic, and critical care therapeutic areas in China and Asia-Pacific markets.
2. Licensing and Royalty Revenue: Revenue from out-licensing arrangements including royalties on net sales, such as the Lerodalcibep license agreement with LIB Therapeutics and commercialization agreements with partners like Everest Medicines.
3. Commercialization Services: Providing commercialization services for partners' products through Hasten's established sales and marketing organization, generating service fees.

Pricing tiers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels5 records

Core offering

Hasten is an integrated biopharmaceutical company that develops, manufactures and commercializes branded originator drugs in chronic disease (cardiovascular, metabolic) and critical care therapeutic areas across China and Asia-Pacific. Its commercial portfolio comprises seven established drugs acquired from Takeda, Roche and Celltrion — including Edarbi, Blopress, Basen, Actos, Ebrantil, Rocephin and Stilamin — alongside the in-licensed innovative biologic Lerodalcibep (HST101), a third-generation PCSK9 inhibitor in Phase 3 development for hypercholesterolemia.

Product overview

Hasten is an innovative biopharmaceutical company established in 2020, integrating R&D, production, and commercial promotion across the full industry chain. The company focuses on chronic disease and acute/critical care therapeutic areas. Its product portfolio comprises two categories: (1) Seven established originator drugs acquired from Takeda and Roche, including antihypertensives 易达比® (Edarbi®), 必洛斯® (Blopress®), 亚宁定® (Ebrantil®); metabolic drugs 倍欣® (Basen®), 艾可拓® (Actos®); and critical care antibiotics 罗氏芬® (Rocephin®) and 思他宁® (Stilamin®); and (2) One in-development innovative drug HST101 (Lerodalcibep), a third-generation PCSK9 inhibitor licensed from LIB Therapeutics for Greater China. The company operates across Mainland China, Hong Kong, Macau, Taiwan, and Pan-Asia Pacific regions.

Differentiator

Problem solved

Functional benefit

Brands

• 易达比 (Edarbi): 美阿沙坦钾片，血管紧张素受体拮抗剂（ARB）类强效降压药，用于成人原发性高血压治疗
• 必洛斯 (Blopress)
• 倍欣 (Basen)
• 艾可拓 (Actos)
• 亚宁定 (Ebrantil)
• 罗氏芬 (Rocephin)
• 思他宁 (Stilamin)
• Lerodalcibep (HST101)

Products and services

• Edarbi (易达比) — Azilsartan Medoxomil Potassium Tablets Azilsartan medoxomil potassium tablets, an angiotensin receptor blocker (ARB) class antihypertensive drug for treatment of adult essential hypertension. Acquired from Takeda and sold in mainland China under the 易达比® brand.
• Blopress (必洛斯) — Candesartan Cilexetil Tablets Candesartan cilexetil tablets, an ARB-class antihypertensive drug for cardiovascular treatment. Acquired from Takeda and commercialized in China under the 必洛斯® brand.
• Ebrantil (亚宁定) — Urapidil Hydrochloride Injection Urapidil hydrochloride injection, an antihypertensive agent for critical care use. Acquired from Takeda and sold in mainland China under the 亚宁定® brand.
• Basen (倍欣) — Voglibose Tablets Voglibose tablets, an alpha-glucosidase inhibitor used in diabetes management. Acquired from Takeda and sold in mainland China under the 倍欣® brand.
• Actos (艾可拓) — Pioglitazone Hydrochloride Tablets Pioglitazone hydrochloride tablets, a thiazolidinedione-class antidiabetic agent. Acquired from Takeda and sold in mainland China under the 艾可拓® brand.
• Rocephin (罗氏芬) — Ceftriaxone Sodium for Injection Ceftriaxone sodium for injection, a third-generation cephalosporin antibiotic for anti-infection treatment in critical care settings. Acquired from Roche and commercialized in China under the 罗氏芬® brand.
• Stilamin (思他宁) — Somatostatin Injection Somatostatin injection for gastrointestinal bleeding, pancreatic and intestinal fistula treatment, and pancreatic postoperative complications. Acquired from Merck and sold under the 思他宁® brand in Greater China and Switzerland, where Hasten holds MAH rights.
• Lerodalcibep (HST101) — Third-Generation PCSK9 Inhibitor Adnectin-based fusion protein administered as a monthly subcutaneous injection (1.2 mL volume) with room-temperature stability up to 6 months below 25°C, in Phase 3 development for LDL-C reduction in patients with hypercholesterolemia, including HeFH, and atherosclerotic cardiovascular disease. Licensed from LIB Therapeutics for Greater China development and commercialization.

Quantifiable outcome

• Achieved double-digit revenue growth since commercialization
• +3 more outcomes

Named customers9 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

13 partnerships are on record, tiered major, supporting and core.

• Everest Medicines (云顶新耀)majorChannel Partner/ Reseller/ Distributor · 11 December 2025Two strategic agreements: (1) Commercialization service agreement for 6 mature products in China covering critical care, cardiovascular and metabolism; (2) License agreement for Lerodalcibep in Greater China. RMB 200 million refundable deposit paid.
• DKSH (大昌华嘉)supportingChannel Partner/ Reseller/ Distributor · 1 October 2025Distribution partnership in Thailand for overseas product registration, market expansion, and cGMP compliance. DKSH's local expertise enables Hasten's market entry in Southeast Asia.
• Celltrion (韩国)majorStrategic or Co-development Partner · 28 June 2024Acquisition of 14 branded product commercial rights across 8 Asia-Pacific countries including South Korea, Singapore, Thailand, Australia, Hong Kong. Products span cardiovascular and diabetes therapeutic areas including Actos, Blopress, Nesina, Oseni.
• Naxions (诺信创联)supportingTechnology or Integration · 29 March 2024'Hai Nuo Xin Cheng' strategic cooperation for digital marketing innovation. Naxions provides multi-dimensional digital promotion models to help Hasten efficiently reach healthcare professionals and improve product accessibility.
• China Resources Jiuxin Pharmaceutical (华润九新药业)supportingImplementation/ SI/ Consulting Partner · 19 December 2023Business strategic cooperation for manufacturing services. Jiuxin provides anti-infective drug manufacturing expertise and strict quality management.
• Apeloa Pharmaceutical (普洛药业)supportingImplementation/ SI/ Consulting Partner · 14 December 2023Business strategic cooperation for contract manufacturing and CDMO services. Apeloa provides advanced manufacturing equipment, R&D capabilities, and quality management systems.
• China Resources Medical Commercial Group (华润医药商业集团)coreChannel Partner/ Reseller/ Distributor · 7 November 2023Multiple strategic agreements including import distribution for Stilamin in mainland China, broad market cooperation, and comprehensive strategic collaboration for product commercialization across all channels.
• LIB Therapeutics Inc.coreStrategic or Co-development Partner · 12 September 2023Licensing agreement granting Hasten rights to develop and commercialize Lerodalcibep (HST101) in Greater China. LIB eligible for up to US$325 million including US$20 million upfront and milestones plus royalties. Joint steering committee established for development alignment.
• Roche (罗氏)majorStrategic or Co-development Partner · 4 May 2023Acquisition of Rocephin (ceftriaxone sodium) commercialization rights in mainland China from Roche. Hasten obtained IP, manufacturing, R&D, commercialization and registration rights.
• Sinopharm Jiangsu (国控江苏)supportingChannel Partner/ Reseller/ Distributor · 27 September 2022Digital marketing cooperation under Sinopharm framework. Sinopharm Jiangsu provides e-commerce operations, marketing coverage, and digital platform management services.
• Jointown Group (九州通)majorChannel Partner/ Reseller/ Distributor · 22 September 2022Strategic partnership for out-of-hospital chronic disease management ecosystem. Jointown leverages nationwide distribution network and marketing capabilities to provide comprehensive services including market access and chronic disease management.
• Sinopharm (国药控股)coreChannel Partner/ Reseller/ Distributor · 24 June 2022Strategic partnership framework agreement for chronic disease service ecosystem. Sinopharm provides nationwide distribution network, import supply chain services, marketing coverage, B2B retail, internet hospital projects, and innovative payment solutions.
• Takeda Pharmaceutical (武田制药)coreStrategic or Co-development Partner · 31 March 2022Acquisition of five cardiovascular and metabolic products from Takeda including Yanningding, Yida Bi, Bilosuo, Beixin, and Aiketuo. Takeda continues manufacturing and supply while Hasten holds exclusive China mainland rights.

Scale indicators6 records

Recent moves14 records

Expansion highlights6 records

Broad incumbents

• Novartis: Global pharma with Leqvio (inclisiran), the leading small-interfering RNA PCSK9 therapy, and Entresto for heart failure — directly competes with Lerodalcibep and Edarbi/Blopress respectively, and operates a broad cardiovascular/metabolic portfolio.
• Amgen: Global biotech whose Repatha (evolocumab) is the established PCSK9 monoclonal antibody — directly comparable to Lerodalcibep as a PCSK9-class lipid-lowering therapy, while Amgen operates across multiple therapeutic areas as a broad incumbent.
• AstraZeneca (China): Global biopharmaceutical major with one of the largest cardiovascular/metabolic franchises in China (Crestor, Brilinta, Farxiga); competes with Hasten's acquired brands and Lerodalcibep pipeline while operating as a broad incumbent across many therapy areas.

Emerging players

• Everest Medicines: Hong Kong-listed Chinese biotech focused on in-licensing innovative therapies for Asia-Pacific; currently both a Hasten commercialization partner (Lerodalcibep) and an emerging comparable building China/Asia commercial capability through licensing.
• Innovent Biologics: Hong Kong-listed Chinese biotech with a strong cardiometabolic pipeline (e.g., mazdutide for obesity/diabetes) and established commercial sales force in China — emerging competitor in overlapping cardiometabolic indications where Hasten's pipeline operates.

Direct peers

• CSPC Pharmaceutical Group: Hong Kong-listed Chinese pharma with strong cardiovascular, metabolic, and critical care portfolios sold through hospital channels, plus active in-licensing and innovative pipeline activity — closely mirrors Hasten's integrated R&D, manufacturing, and commercialization model.
• Joincare Pharmaceutical Group: Shenzhen-listed Chinese pharmaceutical company with established cardiovascular, respiratory, and metabolic drug portfolios distributed via hospital and retail channels — direct therapeutic and channel overlap with Hasten.
• Luye Pharma Group: Hong Kong-listed Chinese specialty pharma with cardiovascular and oncology franchises and active Asia-Pacific expansion — comparable in therapeutic focus and cross-border commercialization ambitions.
• China Grand Pharmaceutical and Healthcare Holdings: Hong Kong-listed Chinese specialty pharma with a chronic-disease and critical care focus and a track record of acquiring international brands for the China market — operates a comparable "acquire-and-commercialize" model to Hasten.
• Sino Biopharmaceutical Limited: Large Hong Kong-listed Chinese pharmaceutical company with a substantial branded chronic-disease and cardiometabolic franchise, including cardiovascular and metabolic therapeutics distributed through hospital channels — directly comparable to Hasten's business model and therapeutic focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/hasten-biopharma

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries8 records

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Hasten